Listed

Pacira BioSciences, Inc.

PCRXNasdaqCIK 1396814HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$192.4mRevenue, Q2 FY2026, three months to 2026-06-30$192.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 4, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$192.4mRevenue, Q2 FY2026, three months to 2026-06-30$192.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Report this figure+6.2% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin2.2%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $4.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Revenue: $192.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Report this figure−2.5 pts on a year earlier
  • Net margin2.4%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $4.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Revenue: $192.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Report this figure+5.1 pts on a year earlier
  • Diluted EPS$0.12Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Report this figureSign changed from a year earlier
  • Free cash flow$56.1mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $57.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0001628280-26-052635. Derived: 6-month figure less the 3-month figure.Capital expenditure: $1.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-04, accession 0001628280-26-052635. Derived: 6-month figure less the 3-month figure.Report this figure+502.5% on a year earlier

Last eight quarters

Full statements
Revenue$192.4mOperating margin 2.2%
Diluted EPS$0.12, Q2 FY2026
Free cash flow$56.1m, Q2 FY2026
Pacira BioSciences, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m169Revenue, Q3 FY2024, three months to 2024-09-30$168.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001628280-25-050176.Report this figure187Revenue, Q4 FY2024, three months to 2024-12-31$187.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012297. Derived: 12-month figure less the 9-month figure.Report this figure169Revenue, Q1 FY2025, three months to 2025-03-31$168.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028871.Report this figure181Revenue, Q2 FY2025, three months to 2025-06-30$181.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Report this figure180Revenue, Q3 FY2025, three months to 2025-09-30$179.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001628280-25-050176.Report this figure197Revenue, Q4 FY2025, three months to 2025-12-31$196.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012297. Derived: 12-month figure less the 9-month figure.Report this figure177Revenue, Q1 FY2026, three months to 2026-03-31$177.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028871.Report this figure192Revenue, Q2 FY2026, three months to 2026-06-30$192.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(82.8%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$139.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001628280-25-050176.Revenue: $168.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001628280-25-050176.Report this figure13.2%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $24.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012297. Derived: 12-month figure less the 9-month figure.Revenue: $187.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012297. Derived: 12-month figure less the 9-month figure.Report this figure1.2%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $2.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-30, accession 0001628280-26-028871.Revenue: $168.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028871.Report this figure4.7%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $8.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Revenue: $181.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Report this figure3.5%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $6.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001628280-25-050176.Revenue: $179.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001628280-25-050176.Report this figure1.2%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $2.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012297. Derived: 12-month figure less the 9-month figure.Revenue: $196.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012297. Derived: 12-month figure less the 9-month figure.Report this figure3.9%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $6.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-30, accession 0001628280-26-028871.Revenue: $177.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028871.Report this figure2.2%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $4.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Revenue: $192.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Report this figure
Net margin%(85.1%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$143.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001628280-25-050176.Revenue: $168.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001628280-25-050176.Report this figure8.6%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $16.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012297. Derived: 12-month figure less the 9-month figure.Revenue: $187.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012297. Derived: 12-month figure less the 9-month figure.Report this figure2.8%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $4.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-04-30, accession 0001628280-26-028871.Revenue: $168.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028871.Report this figure(2.7%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$4.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Revenue: $181.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Report this figure3.0%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $5.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001628280-25-050176.Revenue: $179.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001628280-25-050176.Report this figure0.8%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $1.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012297. Derived: 12-month figure less the 9-month figure.Revenue: $196.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012297. Derived: 12-month figure less the 9-month figure.Report this figure1.6%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $2.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-04-30, accession 0001628280-26-028871.Revenue: $177.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001628280-26-028871.Report this figure2.4%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $4.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Revenue: $192.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Report this figure
Diluted EPS$ per share(3.11)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$3.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001628280-25-050176.Report this figurenot reported (Diluted EPS not reported)0.10Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-30, accession 0001628280-26-028871.Report this figure(0.11)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Report this figure0.12Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001628280-25-050176.Report this figurenot reported (Diluted EPS not reported)0.07Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-30, accession 0001628280-26-028871.Report this figure0.12Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001628280-26-052635.Report this figure
Free cash flow$m49.8Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $53.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001628280-25-050176. Derived: 9-month figure less the 6-month figure.Capital expenditure: $4.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001628280-25-050176. Derived: 9-month figure less the 6-month figure.Report this figure31.0Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $33.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012297. Derived: 12-month figure less the 9-month figure.Capital expenditure: $2.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012297. Derived: 12-month figure less the 9-month figure.Report this figure26.9Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $35.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-30, accession 0001628280-26-028871.Capital expenditure: $8.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-30, accession 0001628280-26-028871.Report this figure9.3Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $12.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0001628280-26-052635. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-04, accession 0001628280-26-052635. Derived: 6-month figure less the 3-month figure.Report this figure57.0Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $60.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001628280-25-050176. Derived: 9-month figure less the 6-month figure.Capital expenditure: $3.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001628280-25-050176. Derived: 9-month figure less the 6-month figure.Report this figure43.5Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $43.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012297. Derived: 12-month figure less the 9-month figure.Capital expenditure: $218.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012297. Derived: 12-month figure less the 9-month figure.Report this figure23.0Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $25.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-30, accession 0001628280-26-028871.Capital expenditure: $2.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-30, accession 0001628280-26-028871.Report this figure56.1Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $57.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0001628280-26-052635. Derived: 6-month figure less the 3-month figure.Capital expenditure: $1.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-04, accession 0001628280-26-052635. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$726.4mOperating margin 2.6%
Diluted EPS$0.16, FY2025
Free cash flow$136.7m, FY2025
Pacira BioSciences, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m542Revenue, FY2021, twelve months to 2021-12-31$541.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0001396814-24-000030.Report this figure667Revenue, FY2022, twelve months to 2022-12-31$666.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0001396814-24-000030.Report this figure675Revenue, FY2023, twelve months to 2023-12-31$675.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012297.Report this figure701Revenue, FY2024, twelve months to 2024-12-31$701.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012297.Report this figure726Revenue, FY2025, twelve months to 2025-12-31$726.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012297.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%16.6%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $89.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-29, accession 0001396814-24-000030.Revenue: $541.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0001396814-24-000030.Report this figure9.0%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $60.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-27, accession 0001396814-25-000041.Revenue: $666.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0001396814-24-000030.Report this figure13.0%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $87.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012297.Revenue: $675.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012297.Report this figure(10.5%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$73.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012297.Revenue: $701.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012297.Report this figure2.6%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $19.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012297.Revenue: $726.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012297.Report this figure
Net margin%7.8%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $42.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-29, accession 0001396814-24-000030.Revenue: $541.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0001396814-24-000030.Report this figure2.4%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $15.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-27, accession 0001396814-25-000041.Revenue: $666.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-29, accession 0001396814-24-000030.Report this figure6.2%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $42.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012297.Revenue: $675.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012297.Report this figure(14.2%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$99.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012297.Revenue: $701.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012297.Report this figure1.0%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $7.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012297.Revenue: $726.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012297.Report this figure
Diluted EPS$ per share0.92Diluted EPS, FY2021, twelve months to 2021-12-31$0.92 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-29, accession 0001396814-24-000030.Report this figure0.34Diluted EPS, FY2022, twelve months to 2022-12-31$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-27, accession 0001396814-25-000041.Report this figure0.89Diluted EPS, FY2023, twelve months to 2023-12-31$0.89 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-012297.Report this figure(2.15)Diluted EPS, FY2024, twelve months to 2024-12-31−$2.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-012297.Report this figure0.16Diluted EPS, FY2025, twelve months to 2025-12-31$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-012297.Report this figure
Free cash flow$m79.9Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $125.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-29, accession 0001396814-24-000030.Capital expenditure: $45.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-29, accession 0001396814-24-000030.Report this figure115Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $145.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-27, accession 0001396814-25-000041.Capital expenditure: $30.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-27, accession 0001396814-25-000041.Report this figure139Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $154.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012297.Capital expenditure: $15.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012297.Report this figure179Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $189.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012297.Capital expenditure: $10.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012297.Report this figure137Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $152.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012297.Capital expenditure: $15.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012297.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Pacira BioSciences, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$170.1m6,705,809Reduced−29,534
Doma Perpetual Capital Management LLC2026-06-30$70.5m2,777,794Unchanged
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$61.0m2,406,238Reduced−95,048
DIMENSIONAL FUND ADVISORS LP2026-06-30$53.4m2,103,245Added+42,648
STATE STREET CORP2026-06-30$52.3m2,059,977Added+140,367
D. E. Shaw & Co., Inc.2026-06-30$49.5m1,950,332Reduced−32,392
RENAISSANCE TECHNOLOGIES LLC2026-06-30$44.0m1,733,801Reduced−91,700
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$42.9m1,691,571Reduced−92,478
GOLDMAN SACHS GROUP INC2026-06-30$38.7m1,527,129Reduced−42,787
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$29.4m1,158,693Added+14,873

Recent filings

All 1,291 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Pacira BioSciences, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-1317:54 ETSCHEDULE 13D/AOwnership report, active investor, amended0001104659-26-115589
2026-10-0809:24 ET8-K1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-26-114571
2026-08-0416:30 ET10-QQuarterly reportPeriod 2026-06-300001628280-26-052635
2026-08-0416:03 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628280-26-052527
2026-06-3007:31 ET8-K1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001628280-26-046136
2026-06-1116:32 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits0001628280-26-042525
2026-04-3016:07 ET10-QQuarterly reportPeriod 2026-03-310001628280-26-028871
2026-04-3016:03 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628280-26-028854
2026-03-1219:57 ETSCHEDULE 13D/AOwnership report, active investor, amended0001011438-26-000180
2026-02-2616:16 ET10-KAnnual reportPeriod 2025-12-310001628280-26-012297

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1396814
Tickers
PCRX
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer
Former names
Pacira Pharmaceuticals, Inc. (to 2019-04-09); PACIRA INC (to 2008-11-05); Blue Acquisition Corp (to 2007-04-16)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 08:33 ET. Listed shows no prices and gives no investment advice.